Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

@article{Sterne2005LongtermEO,
  title={Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study},
  author={Jonathan A. C. Sterne and Miguel A. Hern{\'a}n and Bruno Ledergerber and Kate Tilling and Rainer Weber and Pedram Sendi and Martin Rickenbach and James M. Robins and Matthias Egger},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={378-384}
}
BACKGROUND Evidence on the effectiveness of highly active antiretroviral therapy (HAART) for HIV-infected individuals is limited. Most clinical trials examined surrogate endpoints over short periods of follow-up and there has been no placebo-controlled randomised trial of HAART. Estimation of treatment effects in observational studies is problematic, because of confounding by indication. We aimed to use novel methodology to overcome this problem in the Swiss HIV Cohort Study. METHODS Patients… 
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
  • K. Patel, M. Hernán, +4 authors G. Seage
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
With improved long-term survival, continued follow-up is necessary to evaluate the effects of prolonged use of HAART on potential adverse events, immune function, growth, sexual maturation, and quality of life in this population.
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification
TLDR
Delay in modification after failure of regimens that do not contain a protease inhibitor is associated with increased mortality, and protease inhibitor-based regimens are less dependent on early versus delayed switching strategies.
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
TLDR
Although this study shows an association between the detection of resistance at failure and risk of clinical progression, further research is needed to clarify whether resistance reflects poor adherence or directly increases the risk ofclinical events via exhaustion of drug options.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
TLDR
It is estimated that cART halved the average mortality rate in HIV-infected individuals and was greater in those with worse prognosis at the start of follow-up.
Long-Term Effectiveness of Antiretroviral Therapy in China: An Observational Cohort Study from 2003–2014
TLDR
In conclusions, the effectiveness of ART provided by China government health services is the same as that in higher-income countries.
The long term durability of combination antiretroviral therapy in HIV-positive patients across Europe
TLDR
Assessing the long term durability of cART through assessing various clinical, virological and immunological outcomes including mortality in HIV-positive patients across Europe showed that HIV- positive patients on a well-tolerated and fully suppressive cART regimen have a small risk of treatment failure occurring over the next 6 months and could therefore be monitored less frequently.
Clinical Outcome of HIV-Infected Patients with Sustained Virologic Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort
TLDR
Long-term outcome of patients with sustained virologic response on HAART have a low mortality rate over time, driven by immunologic response at the end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected.
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients
TLDR
Compared with other patient groups, injection drug users and patients with advanced immunodeficiency at baseline experience substantially increased rates of AIDS and death up to 6 years after starting HAART.
Effectiveness of antiretroviral treatment in a South African program: a cohort study.
TLDR
HAART provided through these South African government health services seems as effective as that provided in high-income countries, and delays starting HAART contributed to high mortality rates.
IMPACT OF ANTIRETROVIRAL THERAPY ON SURVIVAL IN HIV INFECTED PATIENTS
The main objective of the study is to compare the survival time on antiretroviral treated HIV patients (TG) versus untreated group (NTG). Medical records of confi rmed HIV patients between 1990 -2008
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
TLDR
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
TLDR
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
TLDR
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group.
TLDR
A significant reduction in risk of death after AIDS was observed from the second half of 1996, apparently due to the widespread use of antiretroviral combination therapies.
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
To estimate the net (i.e., overall) effect of highly active antiretroviral therapy (HAART) on time to acquired immunodeficiency syndrome (AIDS) or death, the authors used inverse
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
  • R. Hogg, B. Yip, +4 authors J. Montaner
  • Medicine
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 1999
TLDR
This population-based cohort study confirms that patients initially treated with a triple-drug antiretroviral regimen comprising 2 NRTIs plus protease inhibitor or a non-NRTI have a lower risk of morbidity and death than patients treated exclusively with 2 N RTIs.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
TLDR
The initial drop in mortality and morbidity after the introduction of HAART has been sustained and potential long-term adverse effects associated with HAART have not altered its effectiveness in treating AIDS.
Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland
TLDR
The introduction of antiretroviral combination therapies in a single cohort study explained 50% of the decline in national AIDS surveillance reports and must become an important component of AIDS surveillance systems.
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
TLDR
Although earlier intervention with combination therapy may provide much more effective treatment, ritonavir in patients with advanced disease and extensive previous antiretroviral use is safe and effective, lowers the risk of AIDS complications, and prolongs survival.
Changing patterns of mortality across Europe in patients infected with HIV-1
TLDR
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
...
1
2
3
4
5
...